drugset / Trial / NCT00062127

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

NCT00062127

Phase 1 Completed 35 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with irinotecan may kill more tumor cells. This randomized phase I trial is studying the side effects and best way to give irinotecan and thalidomide in treating patients with metastatic or unresectable solid tumors

Timeline

Start
2003-04
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule Intravenous
Subject Thalidomide Other / unclassified Oral